NYSE:BMYPharmaceuticals
Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress
Bristol Myers Squibb (NYSE:BMY) reported positive late-stage clinical trial results for two multiple myeloma candidates.
The company announced successful Phase III data for mezigdomide in combination with Kyprolis and dexamethasone.
Early data for its CAR T-cell therapy arlocabtagene autoleucel showed a strong response rate with a manageable safety profile.
The results were presented at the European Hematology Association Congress 2026.
Bristol Myers Squibb is a global biopharmaceutical...